secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcus Biosciences, Inc. (RCUS)
CIK:        0001724521
Form:       8-K
Filed at:   2026-08-05T20:07:48+00:00
Accession:  0001724521-26-000042
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcus Q2 net loss $91M, revenue $41M; casdatifan pipeline advances with new collaborations
--------------------------------------------------------------------------------

- Net loss of $91M in Q2 2026 vs. $0 in Q2 2025; revenue fell to $41M from $160M.
- Cash $775M at June 30; expects ~$600M year-end; runway to at least H2 2028.
- Casdatifan: multiple data readouts H2 2026; new collaborations with BMS, Summit, AVEO.
- Gilead relinquishes three board seats; PACIFIC-8 Phase 3 study discontinued.
- Quemliclustat gets EU orphan drug designation; PRISM-1 Phase 3 results due H1 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1724521/000172452126000042/0001724521-26-000042-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1724521/000172452126000042/rcus-20260805.htm
  HTML page:      https://secwatch.observer/filing/0001724521-26-000042

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer